Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.
What Sun files
- Others51
- Important12
- Updates11
- Board Meeting10
- PPTs4
- Results2
SPARC has applied to stock exchanges for reclassification of a group from 'Promoter' to 'Public' category. This move, if approved, could alter the company's ownership structure and increase public float perception.
Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 10, 2026
Sun Pharma Advanced Research Company Limited has informed the Exchange about Monitoring Agency Report for the quarter ended June 30, 2026.
SPARC's Board approved the financial results for the quarter, with a consolidated loss of ₹20.78 Cr. The board also approved reclassifying certain promoter group individuals. During the quarter, 3.85 Cr warrants were allotted preferentially at ₹155.80 each, and a licensing agreement was terminated, refunding $2M.